RESUMEN
Phytoecdysteroids ecdysteron and turkesteron isolated from Ajuga turkestanica (Rgl.) Brig. decrease the manifestations of uremic intoxication in rats with experimental renal pathology induced by a nephrotoxic mixture (containing uranyl acetate and glycerol). Injected in a dose of 5 mg/kg, the drugs restore glomerular filtration level, favor the disappearance of the albuminuria and normalize urinary sediments. The nephroprotector effect of the phytoecdysteroids studied resembles the action of a steroidal anabolic drug nerobol.
Asunto(s)
Ecdisterona/análogos & derivados , Ecdisterona/uso terapéutico , Enfermedades Renales/tratamiento farmacológico , Metandrostenolona/uso terapéutico , Fitoterapia , Animales , Diuresis , Ecdisterona/farmacología , Glicerol , Enfermedades Renales/inducido químicamente , Enfermedades Renales/fisiopatología , Masculino , Metandrostenolona/farmacología , Compuestos Organometálicos , Proteinuria/tratamiento farmacológico , Proteinuria/orina , RatasRESUMEN
Phytoecdysteroids alpha-ecdysone, 2-desoxyecdysterone, ecdysterone, sileneoside A, and turkesterone isolated from Rhaponticum carthamoides (Willd.) IIjin, Silene brahuica Boiss and Ajuga turkestanica (Rgl.) Repeated administration of brig increased the content of erythrocytes and hemoglobin in the blood of intact rats. The most active of them--ecdysterone, sileneoside A, and, particularly turkesterone, cause also a marked effect on red blood regeneration in hemotoxic phenylhydrazine anemia. In its capacity for simulating erythropoiesis turkesterone resembles the well-known steroidal anabolic drug nerobol.
Asunto(s)
Anabolizantes/farmacología , Eritropoyesis/efectos de los fármacos , Metandrostenolona/farmacología , Fitosteroles/farmacología , Anabolizantes/administración & dosificación , Anabolizantes/uso terapéutico , Anemia Hemolítica/tratamiento farmacológico , Animales , Ecdisterona/administración & dosificación , Ecdisterona/análogos & derivados , Ecdisterona/farmacología , Ecdisterona/uso terapéutico , Recuento de Eritrocitos/efectos de los fármacos , Hemoglobinas/metabolismo , Metandrostenolona/administración & dosificación , Metandrostenolona/uso terapéutico , Fenilhidrazinas/toxicidad , Fitosteroles/administración & dosificación , Fitosteroles/uso terapéutico , Ratas , Estándares de Referencia , Relación Estructura-ActividadRESUMEN
The phytoecdisteroids ecdisterone, turkesterone and cyasterone were administered in a dose of 5 mg/kg per os to rats with hepatitis induced by subcutaneous injections of CCl4. Similarly to the anabolic drug nerobol (10 mg/kg), the above agents not only interfere with the manifestation of the hepatic action of CCl4 (in this case the effect of the phytoecdisteroids is more remarkable) but also favour a more rapid normalization, as compared to the control, of functional and metabolic disorders in the liver. The phytoecdisteroids and nerobol noticeably stimulate the recovery of bile secretion, the synthesis of bilirubin and bile acids, cholesterol excretion.
Asunto(s)
Antídotos/uso terapéutico , Intoxicación por Tetracloruro de Carbono/tratamiento farmacológico , Enfermedad Hepática Inducida por Sustancias y Drogas/tratamiento farmacológico , Hígado/efectos de los fármacos , Metandrostenolona/uso terapéutico , Extractos Vegetales/uso terapéutico , Animales , Intoxicación por Tetracloruro de Carbono/complicaciones , Intoxicación por Tetracloruro de Carbono/metabolismo , Enfermedad Hepática Inducida por Sustancias y Drogas/etiología , Enfermedad Hepática Inducida por Sustancias y Drogas/metabolismo , Evaluación Preclínica de Medicamentos , Ecdisterona/análogos & derivados , Ecdisterona/uso terapéutico , Hígado/metabolismo , Masculino , Ratas , Estigmasterol/análogos & derivados , Estigmasterol/uso terapéuticoRESUMEN
Blood coagulation, immunobiochemical, and clinical characteristics were studied in patients with rheumatic fever running a protracted course treated by combined therapy including nerobol. To assess the therapeutic efficacy of nerobol, the patients were divided into 2 groups: Group 1 (30 patients) were administered combined antirheumatic therapy, Group 2 (30 patients) were administered the same + nerobol in a daily dose of 15 mg for 3-4 weeks. The findings evidence a positive effect of the drug on the status of patients in whom rheumatic fever runs a protracted course: blood procoagulative activity is reduced and anticoagulative activity elevated, blood immunobiochemical and clinical characteristics normalized.
Asunto(s)
Coagulación Sanguínea/efectos de los fármacos , Metandrostenolona/uso terapéutico , Enfermedades Reumáticas/tratamiento farmacológico , Adolescente , Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Enfermedades Reumáticas/sangre , Enfermedades Reumáticas/inmunologíaAsunto(s)
Retardo del Crecimiento Fetal/tratamiento farmacológico , Fibrinólisis/efectos de los fármacos , Metandrostenolona/uso terapéutico , Teofilina/análogos & derivados , Niacinato de Xantinol/uso terapéutico , Quimioterapia Combinada , Femenino , Retardo del Crecimiento Fetal/sangre , Fibrinolíticos , Humanos , Metandrostenolona/administración & dosificación , Embarazo , Factores de Tiempo , Niacinato de Xantinol/administración & dosificaciónRESUMEN
Plasma glucose and insulin concentrations were measured during oral (OGTT) and intravenous (IVGTT) glucose tolerance tests in nine patients off- and on-treatment with the anabolic steroid, methandienone (Dianabol). On-treatment, the tolerance tests showed a markedly increased insulin response accompanied by impairment of glucose tolerance, characteristics normally attributed to insulin resistance. However, fasting plasma glucose (FPG) and insulin (FPI) concentrations were significantly reduced, whereas the pattern normally associated with insulin resistance is for both to be raised. IVGTT glucose and insulin profiles were analysed using an algorithm derived from the minimal models of glucose and insulin dynamics originally proposed by R. Bergman and co-workers. Measures for the following parameters were thus obtained: Si, the sensitivity of glucose disposal to insulin; Sg, net insulin independent glucose disposal; phi 1, the integral concentration of insulin delivered during the first phase of insulin secretion relative to the initial increase in glucose concentration above a model-derived threshold; phi 2, the sensitivity of the rate of rise of insulin concentration in the second phase of insulin secretion to the concentration of glucose above a model-derived threshold; kappa, the fractional clearance rate of insulin; and tau 1/2, the insulin half-life. S1 was significantly reduced on treatment by a factor of 4. Sg, phi 1, phi 2 and tau 1/2 were all significantly increased, and kappa was significantly reduced. The increases in Sg and phi 1 both showed significant correlations with the increase in weight on-treatment. The reduction in FPG and FPI can be explained by the combined effects of the increase in Sg and Dianabol-induced resistance to glucagon.(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Insulina/sangre , Metandrostenolona/uso terapéutico , Adulto , Glucemia/metabolismo , Peso Corporal/efectos de los fármacos , Femenino , Prueba de Tolerancia a la Glucosa , Humanos , Resistencia a la Insulina , Masculino , Persona de Mediana Edad , Modelos BiológicosRESUMEN
The results of a 12 month follow-up of 3 groups of age-matched children (7 boys in each group) with an identically malignant course of Duchenne's myodystrophy determined by means of a genealogical analysis are presented. The fastest progression of the disease was observed in children receiving conventional treatment. Untreated children showed slower progression of the disease. In patients on allopurinol treatment the process was somewhat checked or there was some regression of symptomatology.
Asunto(s)
Distrofias Musculares/genética , Alopurinol/uso terapéutico , Niño , Terapia Combinada , Estudios de Seguimiento , Humanos , Masculino , Metandrostenolona/uso terapéutico , Distrofias Musculares/diagnóstico , Distrofias Musculares/terapia , Nandrolona/análogos & derivados , Nandrolona/uso terapéutico , Nandrolona Decanoato , Neostigmina/uso terapéutico , Síndrome , Vitaminas/uso terapéuticoRESUMEN
The influence of anabolic steroids plus phenformin on the course of disease was studied in patients suffering from occlusive vascular diseases. In arteriosclerosis obliterans of the lower limbs the combined therapy led to a higher percentage of improvement than the control group showed. In coronary heart disease there was also a beneficial effect of this treatment. The drugs were found to exert beneficial clinical effects especially in patients with thrombophlebitis migrans and superficial thrombophlebitis. From the results of this study it is concluded that this therapy may be of clinical value in the treatment of patients with occlusive vascular diseases.
Asunto(s)
Arteriosclerosis Obliterante/sangre , Enfermedad Coronaria/sangre , Fibrinólisis/efectos de los fármacos , Metandrostenolona/uso terapéutico , Fenformina/uso terapéutico , Estanozolol/uso terapéutico , Tromboflebitis/sangre , Adulto , Anciano , Arteriosclerosis Obliterante/tratamiento farmacológico , Ensayos Clínicos como Asunto , Enfermedad Coronaria/tratamiento farmacológico , Femenino , Humanos , Masculino , Metandrostenolona/farmacología , Persona de Mediana Edad , Infarto del Miocardio/sangre , Infarto del Miocardio/complicaciones , Infarto del Miocardio/tratamiento farmacológico , Fenformina/farmacología , Estanozolol/farmacología , Tromboflebitis/tratamiento farmacológico , Tromboflebitis/etiología , Várices/sangre , Várices/complicaciones , Várices/tratamiento farmacológicoRESUMEN
The effects of weakly androgenic steroids at minimal doses (norethandrolone 2.5 to 10 mg/day or methandienone 1 mg/day, administered 2 months every trimester) have been studied in 67 patients with Turner syndrome: 37 with 45 XO karyotype and 30 with mosaicism or partial X deletion. Mean bone age at the onset of treatment was 10 4/12 +/- 1 8/12 years, and the mean height retardation, adjusted to parents' height, was 3.7 +/- 1.2 standard deviations. Growth velocity was very significantly increased during the first 3 semesters of treatment. The ratio of bone age to height age, evaluated after 2 years of treatment, did not increase. The adult height reached by 37 treated patients was at the average 1.96 cm higher than that of a control group of 25 adult untreated Turner cases, this difference being not significant. The results varied greatly between individuals, without relation to the type of chromosomal abnormality or the kind and dose of steroid received. The psychological evolution of the treated patients was studied accordingly to their school and/or professional accomplishments. It was satisfactory in most of them. The anabolic treatment and/or the gain in growth velocity during treatment seemed to have positive psychological effect. No side-effects were noticed.
Asunto(s)
Trastornos del Crecimiento/tratamiento farmacológico , Metandrostenolona/uso terapéutico , Noretandrolona/uso terapéutico , Síndrome de Turner/tratamiento farmacológico , Estatura/efectos de los fármacos , Desarrollo Óseo/efectos de los fármacos , Niño , Femenino , Estudios de Seguimiento , Humanos , Estudios Longitudinales , Metandrostenolona/administración & dosificación , Metandrostenolona/efectos adversos , Noretandrolona/administración & dosificación , Noretandrolona/efectos adversos , Factores de Tiempo , Síndrome de Turner/psicologíaAsunto(s)
Aminoácidos/uso terapéutico , Enteritis/tratamiento farmacológico , Metandrostenolona/uso terapéutico , Nandrolona/análogos & derivados , Adulto , Enfermedad Crónica , Quimioterapia Combinada , Femenino , Humanos , Masculino , Persona de Mediana Edad , Nandrolona/uso terapéutico , Nandrolona Decanoato , Pirazoles/uso terapéuticoRESUMEN
Administration of phytoecdisteroides ecdisterone and turkesterone in the dose of 5 mg/kg and anabolic steroid preparation nerobol in the dose 10 mg/kg in rats with experimental diabetes removes the activation of respiration under all metabolic conditions of rats liver mitochondria revealing at given pathology. The normalized effect of phytoecdisteroides on the cells energetic processes is observed on the 7th day of the administration. The same effect of nerobol is revealed at more prolonged (15 days) administration.
Asunto(s)
Anabolizantes/uso terapéutico , Diabetes Mellitus Experimental/tratamiento farmacológico , Mitocondrias Hepáticas/efectos de los fármacos , Animales , Colestenonas/uso terapéutico , Diabetes Mellitus Experimental/metabolismo , Evaluación Preclínica de Medicamentos , Ecdisterona/uso terapéutico , Metabolismo Energético/efectos de los fármacos , Masculino , Metandrostenolona/uso terapéutico , Mitocondrias Hepáticas/metabolismo , Fosforilación Oxidativa/efectos de los fármacos , Consumo de Oxígeno/efectos de los fármacos , Extractos Vegetales/uso terapéutico , Ratas , Factores de TiempoAsunto(s)
Anabolizantes/uso terapéutico , Distrofias Musculares/tratamiento farmacológico , Adolescente , Adulto , Anabolizantes/efectos adversos , Anabolizantes/metabolismo , Animales , Niño , Preescolar , Congéneres del Estradiol/uso terapéutico , Femenino , Hormona del Crecimiento/fisiología , Hormona del Crecimiento/uso terapéutico , Humanos , Masculino , Metandriol/uso terapéutico , Metandrostenolona/uso terapéutico , Metiltestosterona/uso terapéutico , Persona de Mediana Edad , Proteínas Musculares/biosíntesis , Músculos/efectos de los fármacos , Músculos/metabolismo , Distrofias Musculares/genética , Distrofias Musculares/metabolismo , Distrofia Muscular Animal/tratamiento farmacológico , Distrofia Muscular Animal/metabolismo , Unión Proteica/efectos de los fármacos , Ratas , Testosterona/uso terapéutico , Transcripción Genética/efectos de los fármacosAsunto(s)
Anemia Aplásica/tratamiento farmacológico , Metandrostenolona/uso terapéutico , Oximetolona/uso terapéutico , Estanozolol/uso terapéutico , Adolescente , Adulto , Anemia Aplásica/etiología , Femenino , Humanos , Recuento de Leucocitos , Linfocitos , Masculino , Persona de Mediana Edad , PronósticoAsunto(s)
Anemia Hipocrómica/tratamiento farmacológico , Metandrostenolona/uso terapéutico , Adolescente , Adulto , Anemia Hipocrómica/enzimología , Enfermedad Crónica , Evaluación de Medicamentos , Quimioterapia Combinada , Femenino , Humanos , Isoenzimas/sangre , L-Lactato Deshidrogenasa/sangre , Malato Deshidrogenasa/sangre , Persona de Mediana EdadRESUMEN
In three series of experiments of 120, 49 and 180 days in duration 36 test subjects were exposed to clinostatic and antiorthostatic hypokinesia. Human requirements for various nutrients were defined under hypokinetic conditions. It was demonstrated that during bed rest exercises together with adequate nutrition and after bed rest certain nutrients can serve as efficient countermeasures against metabolic changes.
Asunto(s)
Reposo en Cama , Fenómenos Fisiológicos de la Nutrición , Adulto , Desoxicorticosterona/uso terapéutico , Heces/análisis , Humanos , Masculino , Metandrostenolona/uso terapéutico , Persona de Mediana Edad , Fenómenos Fisiológicos de la Nutrición/efectos de los fármacos , Necesidades Nutricionales , Hormonas Neurohipofisarias/uso terapéutico , Postura , Factores de Tiempo , Equilibrio Hidroelectrolítico/efectos de los fármacosAsunto(s)
Amilasas/sangre , Anabolizantes/uso terapéutico , Proteínas en la Dieta/administración & dosificación , Pancreatitis/enzimología , Prednisolona/uso terapéutico , Enfermedad de Addison/tratamiento farmacológico , Enfermedad de Addison/enzimología , Enfermedad Crónica , Humanos , Metandriol/uso terapéutico , Metandrostenolona/uso terapéutico , Pancreatitis/tratamiento farmacológico , Tripsina/sangre , Inhibidores de Tripsina/sangreRESUMEN
A two compartment, double-blind, randomized, parallel study was performed comparing methandrostenolone with placebo in the treatment of osteoporosis. The duration of the study was 24 mo. Dependent parameters included total body calcium (TBCa), measured by neutron activation analysis: bone mineral content of the radius (BMC), measured by photon absorptiometry; and total body potassium (TBK), measured by total body counting. A significant increase in TBK occurred in the treated group, primarily in the first 6 mo; thereafter the TBK remained fairly constant. No significant changes in bone mass occurred, except the 6 mo TBCa measurement increased by 11 grams for the methandrostenolone group and decreased by 6 grams for the placebo group (p = .05). Other evidence also suggests that anabolic steroids may not produce sustained uncoupling of bone formation and bone resorption in osteoporosis. If methandrostenolone is capable of producing an increment in bone mass in osteoporosis, it was not readily observable with the sensitivity of the techniques employed in this study